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Background: Information on carotid intima media thickness (C-IMT) and plaque (C-IMT+P) have been shown to improve coronary heart disease 
(CHD) risk prediction. Similarly a single nucleotide polymorphism on chromosome 9p21, rs10757274 (9p21) improves CHD risk prediction in whites. 
However, 9p21 is not associated with C-IMT. We evaluated whether the addition of 9p21to C-IMT+P further improves CHD risk prediction in the ARIC 
study.
Methods: White participants in the ARIC study (n=9338) were included. Cox proportional hazard models were used to estimate the 10 year ARIC 
coronary risk score (ARS). C-IMT (categorized as <25th, 25th -75th and >75th percentile) + plaque information (C-IMT+P) and 9p21 were added 
separately and then together to the ARS. Area under the receiver operating characteristic curve (AUC), calibration of model using Grønnesby Borgan 
test, net reclassification index (NRI), integrated discrimination index (IDI) and number of individuals reclassified were estimated.
Results: Over a mean follow up of 14.7±3.7 years, there were 1231 incident CHD events. The AUC of the ARS only model was 0.748 while it 
was 0.751, 0.763 and 0.766 for the ARS + 9p21, ARS + C-IMT+P and ARS + C-IMT+P + 9p21 models respectively. The percentage of individuals 
reclassified, model calibration and NRI and IDI when the various models were compared to the ARS only model are shown in the table
Conclusion: Addition of 9p21 allele information to C-IMT+P further improves CHD risk prediction in the ARIC study. 
Comparison of various risk prediction models with respect to reclassification, goodness of fit, NRI and IDI
ARS only ARS+9p21 allele ARS+ C-IMT/plaque (*) ARS+C-IMT/plaque + 9p21allele (*)
% reclassified (#) - 8.9 (n=828) 24.7% (n=2305) 25.9% (n=2416)
G-B goodness of fit test (p value) 15.75 (p=0.07) 17.6 (p=0.04) 14.48 (p=0.11) 15.27 (p=0.08)
NRI (%) (#) - -0.5 8.3 9.8
Clinical NRI (%) (#) - 4.1 25.01 28.6
IDI (#) - 0.002 0.013 0.016
(#) Comparison of models to the ARS only model
(*) Comparison of ARS+C-IMT/plaque+9p21 allele to ARS+C-IMT/plaque: % reclassified 8.6% (n=803), NRI 1.5%, clinical NRI 6.2%, IDI 0.002,
G-B: Grønnesby Borgan test of model calibration; NRI: Net reclassification index; clinical NRI: NRI in the intermediate (5-20% risk groups); IDI: 
Integrated discrimination index
